← Back to Search

Janus Kinase (JAK) Inhibitor

Ruxolitinib cream for Atopic Dermatitis

Phase 2
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants with diagnosis of AD for at least 6 months
Participants with AD affecting up to a total of 20% BSA (face and/or neck plus other body areas)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 2, 4 and 8
Awards & highlights

Study Summary

This trial is testing a new cream for people with atopic dermatitis on their head and/or neck. The cream will be compared to a placebo cream to see if it is more effective and safe. If it is, people will use it for 4 more weeks to see if it helps in the long term.

Eligible Conditions
  • Atopic Dermatitis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with Alzheimer's disease for at least 6 months.
Select...
You have a certain type of skin condition called AD that affects up to 20% of your body, including your face, neck, and other areas.
Select...
You have a skin condition called atopic dermatitis that affects at least 0.5% of your face and/or neck.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 2, 4 and 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 2, 4 and 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Double-Blind Period: Proportion of participants who achieve an EASI75 of the head and neck region
Secondary outcome measures
Number of treatment-related adverse events
Proportion of participants who achieve an EASI75 of the head and neck region
Proportion of participants who achieve overall EASI75

Trial Design

2Treatment groups
Experimental Treatment
Group I: Open Label Extension: Ruxolitiib cream 1.5%Experimental Treatment1 Intervention
Patients will be treated with Ruxoltinib cream 1.5% twice per day (BID) during the open label extension period. Participants who complete the double-blind period will continue into this open-label extension period for an additional 4 weeks of treatment.
Group II: Double-blind Period: vehicle cream or Ruxolitinib cream 1.5% BIDExperimental Treatment2 Interventions
Participants will be treated with ruxolitinib cream 1.5% or vehicle cream twice a day (BID) in a double-blind fashion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ruxolitinib cream
2022
Completed Phase 3
~1790
Vehicle
2013
Completed Phase 3
~5070

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
361 Previous Clinical Trials
54,973 Total Patients Enrolled
Haq Nawaz, MDStudy DirectorIncyte Corporation
5 Previous Clinical Trials
180 Total Patients Enrolled

Media Library

Ruxolitinib Cream (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05127421 — Phase 2
Atopic Dermatitis Research Study Groups: Double-blind Period: vehicle cream or Ruxolitinib cream 1.5% BID, Open Label Extension: Ruxolitiib cream 1.5%
Atopic Dermatitis Clinical Trial 2023: Ruxolitinib Cream Highlights & Side Effects. Trial Name: NCT05127421 — Phase 2
Ruxolitinib Cream (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05127421 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Nevada
California
How old are they?
65+
What site did they apply to?
Science
What portion of applicants met pre-screening criteria?
Met criteria
~23 spots leftby Mar 2025